Researchers at the Korea Institute of Science and Technology (KIST) have announced a new discovery in the fight against melanoma. The study, published in the journal Molecular Cancer, reveals a new mechanism behind drug resistance in melanoma and proposes potential strategies to overcome it. Led by Dr. Tackhoon Kim, the research team identified that melanomas…
St. Jude pioneers gene editing and structural biology to advance pediatric research
After establishing her lab at Cornell in 2019 and achieving notable success with publications in top journals, Liz Kellogg, Ph.D., associate member in the department of Structural Biology at St. Jude Children’s Research Hospital received a unique opportunity. St. Jude Children’s Research Hospital had embarked on a major expansion of its structural biology and genome…
Preparing for the golden age of small molecule oncology drugs
Small-molecule drugs have been a mainstay of medicine for over a century, including many of the most impactful pharmaceuticals in human history, such as aspirin and penicillin. Recently, though, biologics—or large-molecule drugs—have become more popular. In fact, in 2016, eight out of 10 of the best-selling drugs globally were biologics. However, small-molecule drugs are experiencing…
FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda
The FDA has signed off on two novel therapies targeting rare pediatric cancers. Novartis’ Lutathera targets aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in children 12 and up, while Day One Biopharma’s Ojemda (tovorafenib) tackles treatment-resistant BRAF-mutated relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation These approvals offer…